Form 4: Exelixis EVP & General Counsel Hessekiel Sells 25,000 Shares

Jeffrey Hessekiel, EVP & General Counsel of Exelixis, sold 25,000 shares of common stock at an average price of $28.39 on October 28, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Summary

• Jeffrey Hessekiel, the EVP & General Counsel of Exelixis, sold 25,000 shares of Exelixis common stock on October 28, 2024.
• The sale was executed at a weighted average price of $28.39 per share, with individual transactions ranging from $28.11 to $28.53.
• The transaction was conducted under a pre-arranged Rule 10b5-1 trading plan adopted on February 29, 2024.
• Following the transaction, Hessekiel directly owns 580,325 shares, which includes 236,022 shares underlying restricted stock units (RSUs).
• Hessekiel also indirectly owns shares through the Exelixis, Inc. 401(k) Plan.

Sentiment

Score: 5

Explanation: This is a neutral disclosure of a stock sale by an executive. It doesn't inherently indicate positive or negative sentiment about the company's prospects.

Industry Context

This Form 4 filing is a routine disclosure of insider trading activity. It provides transparency into the transactions of company executives and their holdings in the company's stock. It is common for executives to use 10b5-1 trading plans to sell shares over time to avoid accusations of insider trading based on non-public information.

Comparison to Industry Standards

• Insider trading activity is closely monitored in the pharmaceutical industry, with companies like Amgen, Gilead Sciences, and Biogen also subject to similar reporting requirements.
• The use of 10b5-1 trading plans is a common practice among executives in publicly traded companies to manage their stock holdings while avoiding potential conflicts of interest.
• The size and frequency of insider transactions can vary significantly depending on the individual's compensation structure, personal financial planning, and company performance.

Stakeholder Impact

• The sale of shares by an executive could be perceived negatively by some shareholders, but the use of a pre-arranged trading plan mitigates concerns about insider trading.
• The transaction has no direct impact on employees, customers, suppliers, or creditors.

Key Dates